On Sept. 13, 2024, a panel of the Inquiry Committee approved a consent agreement between BCCNM and the registrant to address practice and conduct issues that occurred from April to November 2023 involving the registrant diverting controlled-class medications for their personal use. The registrant willingly falsified documentation concealing the drug diversion and at times tampered with packaging replacing the controlled substance with an uncontrolled substance. The registrant also accessed patient information for patients not under their care.
The registrant was diagnosed with and admitted to a disability with a causal relationship to the conduct and practice issues via an independent medical evaluation and they have agreed to comply with the treatment recommendations.
The registrant has voluntarily agreed to terms equivalent to a limit and/or condition on their practice, including:
- A suspension of their nursing registration for one week for replacing medications in packages that they did not belong to.
- A reprimand for falsification of records to conceal their diversion activities and for accessing patient information for patients not under their care.
- Enrollment in, and regular reports from, a medical monitoring agency regarding compliance with treatment recommendations including remaining abstinent from psychoactive substances.
- Completion of a number of CBT sessions prior to returning to work, with an agreement to complete a minimum of 15-20 sessions in total.
- Disclosure of treatment recommendations to relevant employer representative(s).
- A limit impacting access to and handling of controlled-class medications, with concurrent medical monitoring, to support the stable return to fitness to practice.
- A limit to working day shifts only for a term.
- A limit restricting them from acting as the nurse-in-charge, working more than full-time hours, having supervision over students and/or being involved in orientation of new staff for a term.
- Indirect supervision of their nursing practice for 12 months to monitor their activities related to controlled-class medications to assess whether there is a pattern suggestive that drug diversion is recurring.
The Agreement will remain in place for a minimum of three years of continuous nursing practice.
The name of the registrant has been withheld in accordance with section 39.3 (4) (a) of the
Health Professions Act for the purposes of not identifying a registrant or their personal health information respecting the condition that impaired their ability to practice nursing.
The Inquiry Committee is satisfied that the terms will protect the public.